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Abstract: The responsiveness of central noradrenergic systems to stressors 
and cocaine poses norepinephrine as a potential common mechanism through 
which drug re-exposure and stressful stimuli promote relapse. This study 
investigated the role of noradrenergic systems in the reinstatement of 
extinguished cocaine-induced conditioned place preference by cocaine and 
stress in male C57BL/6 mice. Cocaine- (15 mg/kg, i.p.) induced conditioned 
place preference was extinguished by repeated exposure to the apparatus in 
the absence of drug and reestablished by a cocaine challenge (15 mg/kg), 
exposure to a stressor (6-min forced swim (FS); 20–25°C water), or 
administration of the -2 adrenergic receptor (AR) antagonists yohimbine 
(2 mg/kg, i.p.) or BRL44408 (5, 10 mg/kg, i.p.). To investigate the role of 
ARs, mice were administered the nonselective β-AR antagonist, propranolol 
(5, 10 mg/kg, i.p.), the -1 AR antagonist, prazosin (1, 2 mg/kg, i.p.), or the 
-2 AR agonist, clonidine (0.03, 0.3 mg/kg, i.p.) before reinstatement testing. 
Clonidine, prazosin, and propranolol failed to block cocaine-induced 
reinstatement. The low (0.03 mg/kg) but not high (0.3 mg/kg) clonidine dose 
fully blocked FS-induced reinstatement but not reinstatement by yohimbine. 
Propranolol, but not prazosin, blocked reinstatement by both yohimbine and 
FS, suggesting the involvement of β-ARs. The β-2 AR antagonist ICI-118551 
(1 mg/kg, i.p.), but not the β-1 AR antagonist betaxolol (10 mg/kg, i.p.), also 
blocked FS-induced reinstatement. These findings suggest that stress-induced 
reinstatement requires noradrenergic signaling through β-2 ARs and that 
cocaine-induced reinstatement does not require AR activation, even though 
stimulation of central noradrenergic neurotransmission is sufficient to 
reinstate. 
Keywords: relapse, norepinephrine, propranolol, prazosin, clonidine, beta 
adrenergic receptors 
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Introduction 
The sudden reemergence of cocaine craving even after 
protracted periods of abstinence and the resulting relapse of drug use 
represent formidable obstacles to the effective management of cocaine 
addiction. Anecdotal reports and clinical and preclinical research have 
identified stress and cocaine re-exposure as likely precipitating events 
for drug relapse (Shaham et al, 2000a, 2000b, 2003; Sinha, 2001; 
Stewart, 2003; Lu et al, 2003). Understanding the neurobiological 
mechanisms that contribute to the relapse of drug use in response to 
these stimuli should lead to the development of new and more 
effective approaches for treating addiction. 
The preclinical study of relapse involves the use of 
reinstatement protocols in which the ability of various stimuli to 
reestablish extinguished drug-seeking behavior is examined (Shaham 
et al, 2003). For example, in rats and monkeys, cocaine administration 
or exposure to a variety of stressors will reinstate extinguished lever 
pressing that was previously reinforced by cocaine delivery (see 
Shaham et al, 2000a, 2000b, 2003; Sinha, 2001; Stewart, 2003; Lu et 
al, 2003 for reviews). Relapse can also be investigated using a 
conditioned place preference reinstatement approach in which the 
ability of stimuli to reestablish extinguished preference for a previously 
cocaine-paired environment is examined (Tzschentke, 2007). In mice, 
extinguished cocaine-induced conditioned place preference can be 
reinstated by administration of a priming injection of cocaine (Itzhak 
and Martin, 2002; Orsini et al, 2008) or by exposure to stressors, 
including social stress (Ribeiro Do Couto et al, 2006), uncontrollable 
electric footshock (Redila and Chavkin, 2008), or forced swim (Kreibich 
and Blendy, 2004). The use of mouse reinstatement models is 
important in that it should facilitate the application of genetic 
approaches not available in other species to further advance 
understanding of relapse substrates. 
The responsiveness of central noradrenergic systems to both 
stressors (Abercrombie et al, 1988; Tanaka et al, 1991; Finlay et al, 
1995) and cocaine (Reith et al, 1997; Li et al, 1996) poses 
norepinephrine (NE) as a potential common mechanism through which 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Neuropsychopharmacology, Vol. 35, No. 11 (October 2010): pg. 2165-78. DOI. This article is © Nature Publishing Group 
(Macmillan Publishers Limited)] and permission has been granted for this version to appear in e-
Publications@Marquette. Nature Publishing Group (Macmillan Publishers Limited) does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Nature Publishing 
Group (Macmillan Publishers Limited). 
4 
 
drug re-exposure and stressful environmental stimuli promote relapse. 
Accordingly, previous studies have suggested that antagonizing 
adrenergic receptors (ARs; Leri et al, 2002; Zhang and Kosten, 2005) 
or suppressing noradrenergic neurotransmission (Erb et al, 2000; Platt 
et al, 2007) can attenuate cocaine seeking, whereas augmenting 
adrenergic neurotransmission through antagonism of -2 adrenergic 
autoreceptors (Lee et al, 2004; Feltenstein and See, 2006; Fletcher et 
al, 2008; Brown et al, 2009) or blockade of reuptake (Platt et al, 
2007; but see Schmidt and Pierce, 2006) can evoke cocaine seeking 
as measured using reinstatement protocols. Considering that in human 
cocaine addicts, drug craving is associated with a robust peripheral 
adrenergic response (Sinha et al, 2003) that seems to be augmented 
during early withdrawal (McDougle et al, 1994) and that repeated 
cocaine exposure produces long-lasting adaptations within central 
noradrenergic systems that may lead to enhanced noradrenergic 
responsiveness during stress (Belej et al, 1996; Macey et al, 2003; 
Baumann et al, 2004; Beveridge et al, 2005; Lanteri et al, 2008), 
central noradrenergic signaling may represent an important 
therapeutic target for the prevention of relapse (Weinshenker and 
Schroeder, 2007; Smith and Aston-Jones, 2008; Sofuoglu and Sewell, 
2009). 
This study investigated the role of noradrenergic systems in the 
reinstatement of extinguished cocaine-induced conditioned place 
preference by cocaine and stress in adult male C57 BL/6 mice. The 
effects of the -1 AR antagonist, prazosin, the β-AR antagonists, 
propranolol, betaxolol, and ICI-118551, and the -2 AR agonist, 
clonidine, on reinstatement by cocaine, forced swim (FS) stress, 
and/or the -2 AR antagonist, yohimbine, were examined. Our findings 
suggest that noradrenergic activation of β-2 ARs is selectively involved 
in stress-induced reinstatement. 
Materials and Methods 
Subjects 
A total of 250 male C57BL/6 mice (8–9 weeks old) were used 
(Harlan). Mice were housed singly in a temperature- and humidity-
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controlled, AAALAC-accredited animal facility under a 12/12 h 
light/dark cycle (lights on at 0700 hours) and had access to food and 
water at all times, except when in the experimental chambers. All 
procedures were carried out in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted and promulgated by the 
NIH. 
Drugs 
Cocaine HCl was acquired from the National Institute on Drug 
Abuse (NIDA) through the NIDA Drug Supply Program. Clonidine HCl, 
±propranolol HCl, betaxolol HCl, ICI-118551 HCl, and yohimbine HCl 
were purchased from Sigma-Aldrich. BRL 44408 maleate was acquired 
from Tocris Bioscience. Yohimbine, prazosin, and clonidine were 
dissolved in sterile water. Cocaine, propranolol, betaxolol, ICI-118551, 
and BRL 44408 were dissolved in saline (0.9% NaCl solution). All drug 
solutions were administered i.p. in a volume of 0.1 ml per 20 g body 
mass. 
Equipment 
Behavioral testing was conducted using four ENV-3013 mouse 
place preference chambers from Med-Associates, Inc. The stainless 
steel and polyvinyl chloride chambers consisted of three distinct 
compartments separated by 5 cm wide × 5.9 cm high manual guillotine 
doors. The two 46.5 × 12.7 × 12.7 cm3 side compartments consisted 
of a white compartment with a 6.35 × 6.35 mm2 stainless steel mesh 
floor and a black compartment with a stainless steel grid rod floor 
consisting of 3.2 mm rods spaced 7.9 mm apart. The side 
compartments were attached by a gray-colored 7.2-cm-long center 
compartment with a smooth floor. The clear tops of the compartments 
were hinged to permit placement and removal of the mice. Ceiling 
lights were attached to each top. To balance unconditioned side 
preference, only the light in the black compartment was illuminated 
during training or testing. Automated data collection was accomplished 
using photobeams (six beams for the white and black test areas and 
two beams for the center gray area), which were evenly spaced across 
the length of the chamber and interfaced with a computer containing 
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Med-PC software. Using this automated photobeam system, entry into 
a side compartment was defined as consecutive breaks of the first two 
photocell beams in that compartment located adjacent to the door 
separating that compartment from the center compartment. Exiting of 
a side compartment (and entry into the center compartment) was 
indicated by occlusion of the beams in the center compartment. 
Cocaine-Induced Conditioned Place Preference 
Cocaine-induced conditioned place preference was established 
using a design in which one of the side compartments was randomly 
designated as the cocaine compartment and the other as the saline 
compartment. On the first day of the procedure, mice were placed into 
the center compartment of the chamber and provided free access to 
both side compartments for 30 min in the absence of saline or cocaine 
pretreatment to determine preconditioning preference. During the 8-
day conditioning phase of the experiment, mice received cocaine 
(15 mg/kg, i.p.) and saline injections on alternating days, after which 
they were confined to the randomly designated treatment-appropriate 
compartment for 30 min. After the final conditioning session, mice 
were tested for the expression of cocaine-induced conditioned place 
preference by once again placing them into the center compartment of 
the chamber and providing them with free access to the side 
compartments for 30 min. Conditioned place preference was defined as 
the change in time spent (seconds) within the cocaine-paired 
compartment after conditioning when compared with the initial 
preconditioning session. The 15 mg/kg cocaine dose was selected on 
the basis of results of a preliminary study in which the ability of 
various cocaine doses to produce place preference was examined 
(Figure 1a). 
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Figure 1 Induction and reinstatement of cocaine-induced conditioned place 
preference. Cocaine dose-dependently induced conditioned place preference with peak 
effects at the 15 mg/kg (i.p.) dose. Data in (a) represent the mean change in time 
spent (sec±SE) in the cocaine-paired compartment between the pre- and post-
conditioning test sessions in mice that were conditioned with various cocaine doses 
(0–30 mg/kg, i.p.; n=10–20/group). On the basis of these data, the 15 mg/kg cocaine 
dose was selected as the conditioning and reinstatement dose for each experiment. (b 
and c) Show the reinstatement of extinguished cocaine-induced conditioned place 
preference by cocaine (Coc; 10 mg/kg, i.p.; n=23; b), physical restraint (Res; n=26; 
b), forced swim (FS; n=16; b), and by the -2 AR antagonists yohimbine (Yoh; 1 and 
2 mg/kg, i.p.; n=23; c) and BRL 44408 (BRL; 2.5, 5, and 10 mg/kg, i.p.; n=6–8; c). 
Data represent the time spent in the Coc compartment (sec±SE) during the 30-min 
reinstatement (Rst) session (filled bars) or during the preceding extinction session 
(open bars). Coc, FS, 2 mg/kg Yoh, and 5 and 10 mg/kg BRL but not Res, 1 mg/kg Yoh 
or 2.5 mg/kg BRL, produced significant reinstatement (*p<0.05 vs Ext). 
Extinction 
After conditioning, daily extinction training was conducted. 
During the extinction sessions, mice were placed into the center 
compartment and once again provided free access to the side 
compartments for 30 min. Mice underwent daily extinction training 
until the preference for the cocaine-paired compartment during the 
session (ie, change in time spent in the cocaine side relative to 
preconditioning values) was reduced by at least 50% compared with 
the post-conditioning test session, at which time reinstatement testing 
was conducted. 
Reinstatement Testing 
The reinstatement sessions were identical to the extinction 
sessions, except that mice received exposure to stressors and/or drug 
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injections before the session. Reinstatement was defined according to 
the time spent in the compartment previously paired with cocaine. 
Mice were tested more than once for reinstatement. Generally, each 
mouse was tested with each of the three reinstating stimuli (cocaine, 
forced swim (FS), and yohimbine) alone and in combination with one 
drug pretreatment and its respective vehicle in counter-balanced order 
to avoid potential sequence effects. Reinstatement sessions were 
separated by additional extinction sessions. Mice were required to 
reach the extinction criterion once again before the next reinstatement 
test was conducted. Initially, separate groups of mice were tested for 
the ability of various stressors and drugs, when delivered in the 
absence of pretreatments, to produce reinstatement. 
Drug-Induced Reinstatement 
Cocaine- and yohimbine-induced reinstatement testing was 
conducted by injecting mice with cocaine (15 mg/kg, i.p.) or yohimbine 
(1 or 2 mg/kg, i.p.) either alone or 30 min after pretreatment with 
clonidine (0.03 and 0.3 mg/kg), propranolol (5 and 10 mg/kg), 
prazosin (1 and 2 mg/kg), betaxolol (10 mg/kg), or ICI-118551 
(10 mg/kg), or their respective vehicles and placing mice into the 
center compartment 5 min later with free access to both sides of the 
compartment for 30 min. Reinstatement by clonidine, propranolol, 
prazosin, betaxolol, and ICI-118551 alone was also tested after 
administration 30 min before the reinstatement session, a time point 
that matched the pretreatment time when these drugs were 
administered before cocaine, yohimbine, or FS during testing. To 
confirm that antagonism of -2 AR by yohimbine may have contributed 
to reinstatement, a separate group of mice was tested for 
reinstatement in response to the highly selective -2 AR antagonist, 
BRL 44408 (2.5, 5, and 10 mg/kg, i.p.). 
Stress-Induced Reinstatement 
FS-induced reinstatement was examined by placing mice into a 
30 cm high × 20 cm deep cylindrical polypropylene container filled with 
water (20–25°C) for 6 min, 30 min after pretreatment with clonidine 
(0.03 and 0.3 mg/kg), propranolol (5 and 10 mg/kg), prazosin (1 and 
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2 mg/kg), or their respective vehicles. After FS, mice were placed back 
into their home cages for 3–4 min before introducing them into the 
center compartment of the place conditioning chamber with free 
access to both of the side compartments for reinstatement testing, as 
described above. Initially, some mice were also tested for 
reinstatement following 5 min of physical restraint using a mouse 
restrainer cone (5.7 cm diameter tapered to 1.2 cm diameter; 11 cm 
length). These mice were also returned to their home cages after 
restraint for 3–4 min before placement into the apparatus for 
reinstatement testing. As propranolol blocked FS-induced 
reinstatement, we also tested the mice for the effects of the selective 
β-1 AR antagonist, betaxolol (10 mg/kg, i.p.), and the selective β-2 AR 
antagonist, ICI-118551 (1 mg/kg, i.p.), on reinstatement after FS. 
Locomotor Testing 
To assist with dose selection, the effects of various doses of 
clonidine, prazosin, and propranolol on locomotor activity were tested 
in 26 mice using an automated AccuScan activity system (AccuScan 
Instruments, Inc., Columbus, OH) consisting of a frame containing 
photocells (eight per cage), in which clear Plexiglas 29.5 cm long × 
19 cm wide × 12.7 cm high cages were placed. Activity was measured 
as total photobeam breaks. During the week before the locomotor 
testing, mice were habituated to the test environment during two 2-h 
sessions. On the test day, mice were placed into the chambers for 2 h 
before the drug administration, after which was measured over a 2-h 
period. The effects of clonidine (0, 0.03, 0.3, and 1 mg/kg, i.p.), 
prazosin (0, 1, 2, and 4 mg/kg, i.p.), and propranolol (0, 5, 10, and 
20 mg/kg, i.p.) were tested in separate groups of mice. Only doses 
that failed to produce statistically significant reductions in activity were 
tested for effects on reinstatement. 
Statistical Analyses 
Place preference during testing, extinction, and reinstatement 
was defined as the time spent (sec) in the designated cocaine 
compartment. The abilities of individual stimuli to reinstate place 
preference in the absence of drug pretreatments were examined 
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statistically using two-tailed Student's t-tests comparing the time 
spent in the cocaine compartment during the previous extinction 
session with that during the reinstatement session. The significance of 
the effects of drug pretreatments on reinstatement by each of the 
stimuli was determined using two-way repeated measures 
reinstatement × drug pretreatment ANOVA followed by post-hoc 
testing using two-tailed Student's t-tests. The significance of dose-
related drug effects on locomotor activity was determined using one-
way (drug dose) ANOVA followed by post-hoc testing using the 
Dunnett's test. For all analyses, significance was defined as p<0.05. 
RESULTS 
Establishment and Reinstatement of Cocaine-Induced 
Conditioned Place Preference 
Dose–response analysis showed that the 15 mg/kg cocaine dose 
was optimal for producing conditioned place preference (n=10–20 
mice per cocaine/veh dose; Figure 1a). Although not shown, significant 
cocaine-induced conditioned place preference, defined as an increase 
in time spent in the cocaine-paired compartment, was observed in 
each of the experiments in which reinstatement was later examined 
(p<0.05 for each experiment). The overall average number of 
extinction sessions before the first reinstatement test session was 
8.757. Overall, 28 mice (out of 224 that underwent conditioning) were 
not tested for reinstatement, because they either did not show 
cocaine-induced conditioned place preference or failed to reach the 
extinction criterion. 
The ability of cocaine and stress to reinstate extinguished 
cocaine-induced place preference is shown in Figure 1b. Administration 
of 15 mg/kg cocaine (t22=4.949; n=23) or FS (t15=3.128; n=16), but 
not restraint (n=26), significantly increased the time spent in the 
cocaine compartment following extinction (p<0.01). 
To determine whether stimulating central noradrenergic 
neurotransmission through antagonism of -2 AR is sufficient to induce 
reinstatement, mice were tested for the ability of yohimbine and the 
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more selective -2A AR antagonist, BRL 44408, to reinstate 
extinguished place preference (Figure 1c). For yohimbine, a two-way 
reinstatement condition (repeated measure) × yohimbine dose (1 vs 
2 mg/kg) ANOVA showed a significant overall effect of reinstatement 
condition (F1,33=5.252; p<0.05) but not yohimbine dose, and a 
significant reinstatement condition × dose interaction (F1,33=4.089; 
p=0.05). The 2 mg/kg (t22=3.371; n=23), but not 1 mg/kg (n=23), 
yohimbine dose produced significant reinstatement (p<0.01). Although 
yohimbine can increase central noradrenergic neurotransmission 
through antagonism of -2 ARs, it also binds to several other 
receptors, including the 5-HT1A receptor, where it functions as an 
antagonist and may produce effects independently of the 
noradrenergic system (Sanger and Schoemaker, 1992; Winter and 
Rabin, 1992). To confirm that -2 AR antagonism is sufficient to 
induce reinstatement, we also tested some mice for reinstatement 
after administration of the selective -2A AR antagonist BRL 44408, 
which has a 50-fold higher affinity for -2A AR relative to 5-HT1A 
receptors (Dwyer et al, 2010). A two-way repeated-measures 
reinstatement condition × BRL 44408 dose (2.5, 5.0, 10.0 mg/kg) 
ANOVA showed a significant overall effect of reinstatement condition 
(F1,6=13.557; p=0.01) but not BRL 44408 dose, and a significant 
reinstatement condition × dose interaction (F2,12=4.222; p<0.05). 
Similar to yohimbine, BRL 44408 dose-dependently reinstated, with 
significant effects observed at the 5 (t6=2.776; p<0.05) and 10 
(t7=2.538; p<0.05), but not at the 2.5 mg/kg BRL 44408 doses. 
Locomotor Testing 
Propranolol, prazosin, and clonidine each produced dose-
dependent reductions in locomotor activity (Figure 2). One-way 
prazosin dose ANOVA examining the effects of 1, 2, and 4 mg/kg 
prazosin on locomotor activity showed a significant overall effect 
(F1,36=3.300; p<0.05). Post-hoc testing using the Dunnett's t-test 
showed that the 4 mg/kg dose, but not the other prazosin doses, 
significantly reduced locomotor activity compared with vehicle-treated 
controls (p<0.01). Similarly, one-way propranolol dose ANOVA 
examining the effects of 5, 10, and 20 mg/kg propranolol on locomotor 
activity showed a significant overall effect (F1,36=3.244; p<0.05). Post-
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hoc testing using the Dunnett's t-test showed that the 20 mg/kg dose, 
but not the other propranolol doses, significantly reduced locomotor 
activity compared with vehicle-treated controls (p<0.05). One-way 
clonidine dose ANOVA examining the effects of 0.03, 0.3, and 1 mg/kg 
clonidine on locomotor activity failed to show a significant overall 
effect of clonidine, despite a near-significant trend (F3,33=2.693; 
p=0.06). Post-hoc testing using the Dunnett's t-test showed that the 
1 mg/kg dose, but not the other clonidine doses, significantly reduced 
locomotor activity compared with vehicle-treated controls (p<0.05). As 
4 mg/kg prazosin, 20 mg/kg propranolol, and 1 mg/kg clonidine 
produced significant reductions in locomotor activity, we chose not to 
test the effects of these doses on reinstatement. 
 
Figure 2 Effects of clonidine (CLO; a), prazosin (PRZ; b), and propranolol (PRO; c) 
or their respective vehicles (Veh) on locomotor activity. To facilitate dose selection, 
mice (n=6–10 per dose) were tested for the effects of CLO, PRZ, and PRO on 
locomotor activity. Data represent locomotor counts (total photobeam breaks) 
measured during a 2-h session that immediately followed drug administration. Each 
drug dose-dependently attenuated locomotor activity (*p<0.05; significant reduction 
vs Veh). 
Reinstatement by Prazosin, Propranolol, Clonidine, 
Betaxolol, and ICI-118551 
To ensure that the -1 AR antagonist prazosin, the β-AR 
antagonists propranolol, betaxolol and ICI-118551, and the -2 AR 
agonist clonidine did not, by themselves, alter preference for the 
cocaine compartment after extinction, we initially examined the ability 
of these drugs, when administered alone, to reinstate extinguished 
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conditioned place preference at the doses to be used (Table 1). 
Whereas prazosin (1 mg/kg; n=12 or 2 mg/kg; n=14), propranolol 
(5 mg/kg; n=8 or 10 mg/kg; n=10), betaxolol (10 mg/kg; n=12), or 
ICI-118551 (5 mg/kg; n=12) failed to alter the amount of time spent 
in the cocaine-paired compartment after extinction, clonidine, at the 
higher (0.3 mg/kg; t12=2.491, p<0.05; n=13) but at not the lower 
(0.03 mg/kg; n=13) dose, produced significant reinstatement 
(p<0.05). 
 
Effects of Clonidine on Reinstatement 
As augmentation of central noradrenergic neurotransmission by 
administration of yohimbine or the selective -2A AR antagonist, BRL-
44408, induced reinstatement, we hypothesized that noradrenergic 
neurotransmission during stress or after cocaine exposure may 
contribute to stress- and cocaine-induced drug seeking. To test this 
hypothesis, mice were tested for FS- or cocaine-induced reinstatement 
after administration of clonidine, an -2 AR agonist that suppresses 
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evoked increases in NE (Florin et al, 1994; Tjurmina et al, 1999) 
presumably by the activation of inhibitory autoreceptors on 
noradrenergic nerve terminals. 
Forced Swim 
The effects of clonidine (0.03 and 0.3 mg/kg, i.p.) on FS-induced 
reinstatement are shown in Figure 3. Clonidine suppressed FS-induced 
reinstatement, but only at the 0.03 mg/kg dose. A total of 27 mice 
were used to test for the effects of 0.03 mg/kg clonidine dose on FS-
induced reinstatement (Figure 3a). Two-way repeated-measures FS × 
clonidine treatment condition ANOVA showed a significant overall 
effect of FS (F1,26=6.199; p<0.05) but not clonidine treatment 
condition on time spent in the cocaine compartment and a significant 
clonidine × FS interaction (F1,26=12.264; p<0.01). Post-hoc 
examination of reinstatement in each group revealed that FS 
significantly reinstated place preference in vehicle-treated but not 
clonidine-treated mice (t26=3.230; p<0.05) and that time spent in the 
cocaine compartment was significantly reduced by clonidine after FS 
(t26=3.012; p<0.05). Nine mice were used to test the effects of the 
0.3 mg/kg clonidine dose on FS-induced reinstatement (Figure 3b). In 
contrast to the 0.03 mg/kg clonidine dose, 0.3 mg/kg clonidine failed 
to block FS-induced reinstatement. Two-way repeated measures FS × 
clonidine treatment condition ANOVA showed a significant overall 
effect of FS (F1,8=6.122; p<0.05), but not of clonidine and no FS × 
clonidine interaction. 
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Figure 3 The The -2 AR agonist clonidine dose-dependently blocks stress-induced 
reinstatement. Data represent the time spent in the cocaine (Coc) compartment 
(sec±SE) during the final extinction session prior to reinstatement testing (Ext) and 
during reinstatement testing after forced swim (FS) after pretreatment with vehicle 
(V) or clonidine (Clo). A significant interaction between FS and Clo was found in mice 
tested at the 0.03 mg/kg (i.p.) Clo dose (a; n=27; p>0.05). Post-hoc testing showed 
that FS increased time spent in the Coc compartment after treatment with V 
(#p<0.05) but not 0.03 mg/kg Clo. Further, time spent in the Coc compartment was 
significantly reduced after 0.03 mg/kg Clo compared with V (@p<0.05). The effect of 
0.3 mg/kg (i.p.) Clo (n=9) on FS-induced reinstatement is shown in b. A significant 
main effect of FS (*p<0.05) but no FS × Clo interaction was found at this dose. 
Cocaine 
The effects of clonidine (0.03 or 0.3 mg/kg, i.p.) on cocaine-
induced reinstatement are shown in Figure 4. Neither clonidine dose 
blocked cocaine-induced reinstatement. The effect of 0.03 mg/kg 
clonidine was tested in 25 mice (Figure 4a). Two-way cocaine × 
0.03 mg/kg clonidine treatment condition ANOVA showed a significant 
overall effect of cocaine priming (F1,24=22.807; p<0.001) on time 
spent in the cocaine compartment. However, no significant main effect 
of clonidine treatment condition or interaction between clonidine 
treatment and cocaine-induced reinstatement was found. In all, 13 
mice were tested for the effect of a 10-fold higher clonidine dose 
(0.3 mg/kg, i.p.) on cocaine-induced reinstatement (Figure 4b). Not 
only did this higher clonidine dose fail to block cocaine-induced 
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reinstatement, but it also tended to augment reinstatement in 
response to cocaine. Similar to the lower clonidine dose, two-way 
cocaine × clonidine treatment condition ANOVA showed a significant 
overall effect of cocaine priming (F1,12=9.319; p=0.01) on time spent 
in the cocaine compartment, with no main effect of clonidine treatment 
condition and no interaction between clonidine treatment and cocaine-
induced reinstatement. 
 
Figure 4 The -2 AR agonist clonidine does not block cocaine-induced 
reinstatement. Data represent the time spent in the cocaine (Coc) compartment 
(sec±SE) during the final extinction session before reinstatement testing (Ext) and 
during reinstatement testing after administration of cocaine (C; 15 mg/kg, i.p.) after 
pretreatment with vehicle (V) or 0.03 mg/kg clonidine (i.p.) (Clo; n=25; a) or with V 
or 0.3 mg/kg Clo (n=13; b). In both cases, significant main effects of C (*p<0.05) but 
no significant C × Clo interactions were found. 
Yohimbine 
The effects of clonidine on yohimbine-induced reinstatement are 
shown in Figure 5. As yohimbine likely reinstates extinguished cocaine 
seeking by blockade of -2 ARs, we anticipated that yohimbine-
induced reinstatement would be attenuated by clonidine. Surprisingly, 
neither the low (ie, 0.03 mg/kg) nor the high (ie, 0.3 mg/kg) clonidine 
dose blocked yohimbine-induced reinstatement. A total of 40 mice 
were tested for the effects of 0.03 mg/kg clonidine on yohimbine-
induced reinstatement (Figure 5a). Two-way repeated-measures 
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ANOVA showed a significant overall effect of yohimbine on time spent 
in the cocaine compartment (F1,39=13.306) but failed to show a 
significant main effect of 0.03 mg/kg clonidine treatment condition or a 
significant interaction between clonidine treatment and yohimbine-
induced reinstatement. We reasoned that our inability to fully block 
yohimbine-induced reinstatement with 0.03 mg/kg clonidine may have 
been dose-related because of the competition for the same receptor 
site. However, when we tested mice with 0.3 mg/kg clonidine (n=38), 
there was little evidence for a reduction of yohimbine-induced 
reinstatement at this dose (Figure 5b). Two-way repeated-measures 
yohimbine-induced reinstatement × 0.3 mg/kg clonidine treatment 
condition ANOVA showed a significant overall effect of yohimbine 
(F1,37=8.507; p<0.01), but no overall effect of clonidine pretreatment 
and no yohimbine reinstatement × clonidine pretreatment interaction. 
 
Figure 5 The -2 AR agonist clonidine does not block yohimbine-induced 
reinstatement. Data represent the time spent in the cocaine (Coc) compartment 
(sec±SE) during the final extinction session prior to reinstatement testing (Ext) and 
during reinstatement testing after administration of yohimbine (Y; 2 mg/kg, i.p.) after 
pretreatment with vehicle (V) or 0.03 mg/kg clonidine (i.p.) (Clo; n=40; a) or with V 
or 0.3 mg/kg Clo (n=38; b). In both cases, significant main effects of Y (*p<0.05) but 
no significant Y × Clo interactions were found. 
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Effects of Prazosin on Reinstatement 
To examine the role of -1 ARs in reinstatement by various 
stimuli, mice were pretreated with the -1 AR antagonist prazosin (2 
and 4 mg/kg) before FS or administration of cocaine or yohimbine. In 
all cases, prazosin failed to alter reinstatement. 
Forced Swim 
The effects of prazosin (1 or 2 mg/kg, i.p.) on FS-induced 
reinstatement are shown in Figure 6. Neither prazosin dose blocked 
reinstatement after FS. The effect of 1 mg/kg prazosin was tested in 
five mice (Figure 6a). Two-way repeated-measures FS × 1 mg/kg 
prazosin treatment condition ANOVA showed a significant overall effect 
of FS (F1,4=12.251; p<0.05) on time spent in the cocaine 
compartment. However, no significant main effect of prazosin 
treatment condition or interaction between prazosin and FS-induced 
reinstatement was found. In all 14 mice were tested for the effect of 
2 mg/kg prazosin on FS-induced reinstatement (Figure 6b). Similar to 
the lower prazosin dose, two-way repeated-measures FS × 2 mg/kg 
prazosin treatment condition ANOVA showed a significant overall effect 
of FS (F1,13=5.368; p<0.05) on time spent in the cocaine 
compartment, with no main effect of prazosin treatment condition and 
no interaction between prazosin and FS. 
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Figure 6 The selective -1 AR antagonist prazosin does not block stress-induced 
reinstatement. Data represent the time spent in the cocaine (Coc) compartment 
(sec±SE) during the final extinction session prior to reinstatement testing (Ext) and 
during reinstatement testing after forced swim (FS) after pretreatment with vehicle 
(V) or 1 mg/kg (i.p.) prazosin (Prz; n=5; a) or pretreatment with V or 2 mg/kg (i.p.) 
Prz (n=14; b). In both cases, significant main effects of FS (*p<0.05) but no FS × Prz 
interactions were found. 
Cocaine 
The effects of prazosin on cocaine-induced reinstatement are 
shown in Figure 7. Neither prazosin dose blocked cocaine-induced 
reinstatement. The effect of 1 mg/kg prazosin was tested in a total of 
11 mice (Figure 7a). Two-way cocaine × 1 mg/kg prazosin treatment 
condition ANOVA showed a significant overall effect of cocaine 
(F1,10=9.000; p<0.05) on time spent in the cocaine compartment. 
However, no significant main effect of prazosin treatment condition or 
interaction between prazosin and cocaine-induced reinstatement was 
found. A total of 13 mice were tested for the effect of 2 mg/kg prazosin 
on cocaine-induced reinstatement (Figure 7b). Similar to the lower 
prazosin dose, two-way cocaine × 2 mg/kg prazosin treatment 
condition ANOVA showed a significant overall effect of cocaine 
(F1,12=17.241; p<0.01) on time spent in the cocaine compartment, 
with no main effect of prazosin treatment condition and no interaction 
between prazosin treatment and cocaine-induced reinstatement. 
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Figure 7 The selective -1 AR antagonist prazosin does not block cocaine-induced 
reinstatement. Data represent the time spent in the cocaine (Coc) compartment 
(sec±SE) during the final extinction session before reinstatement testing (Ext) and 
during reinstatement testing after administration of cocaine (C; 15 mg/kg, i.p.) after 
pretreatment with vehicle (V) or 1 mg/kg (i.p.) prazosin (Prz; n=11; a) or 
pretreatment with V or 2 mg/kg (i.p.) Prz (n=13; b). In both cases, significant main 
effects of C (*p<0.05) but no C × Prz interactions were found. 
Yohimbine 
The effects of prazosin on cocaine-induced reinstatement are 
shown in Figure 8. Neither prazosin dose blocked yohimbine-induced 
reinstatement. The effect of 1 mg/kg prazosin was tested in six mice 
(Figure 8a). Two-way repeated measures yohimbine × 1 mg/kg 
prazosin treatment condition ANOVA showed a significant overall effect 
of yohimbine (F1,5=13.114; p<0.05) on time spent in the cocaine 
compartment. However, no significant main effect of prazosin 
treatment condition or interaction between prazosin and yohimbine-
induced reinstatement was found. In all 15 mice were tested for the 
effect of 2 mg/kg prazosin on yohimbine-induced reinstatement (Figure 
8b). Similar to the lower prazosin dose, two-way repeated-measures 
yohimbine × 2 mg/kg prazosin treatment condition ANOVA showed a 
significant overall effect of yohimbine (F1,14=11.558; p<0.01) on time 
spent in the cocaine compartment, with no main effect of prazosin 
treatment condition and no interaction between prazosin and 
yohimbine. 
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Figure 8 
The selective -1 AR antagonist prazosin does not block yohimbine-induced 
reinstatement. Data represent the time spent in the cocaine (Coc) compartment 
(sec±SE) during the final extinction session prior to reinstatement testing (Ext) and 
during reinstatement testing after administration of yohimbine (Y; 2 mg/kg, i.p.) after 
pretreatment with vehicle (V) or 1 mg/kg (i.p.) prazosin (Prz; n=6; a) or pretreatment 
with V or 2 mg/kg (i.p.) Prz (n=15; b). In both cases, significant main effects of Y 
(*p<0.05) but no Y × Prz interactions were found. 
Effects of Propranolol on Reinstatement 
To examine the role of β-ARs in reinstatement by various 
stimuli, mice were pretreated with the nonselective β-AR antagonist, 
propranolol, before FS or administration of cocaine or yohimbine. 
Propranolol blocked reinstatement by FS and yohimbine, but not 
cocaine. Further, FS-induced reinstatement was more sensitive to 
blockade by propranolol than yohimbine-induced reinstatement. 
Forced Swim 
The effects of propranolol (5 or 10 mg/kg, i.p.) on FS-induced 
reinstatement are shown in Figure 9. Both propranolol doses blocked 
FS-induced reinstatement. The effect of 5 mg/kg propranolol was 
tested in seven mice (Figure 9b). Two-way repeated-measures FS × 
5 mg/kg propranolol treatment condition ANOVA failed to show a 
significant overall effect of propranolol or FS on time spent in the 
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cocaine compartment. However, a significant propranolol × FS 
interaction was observed (F1,6=8.598; p<0.05). Post-hoc examination 
of reinstatement in each group revealed that FS significantly reinstated 
place preference in vehicle- but not 5 mg/kg propranolol-treated mice 
(t6=4.32; p<0.05). In all 16 mice were tested for the effects of 
10 mg/kg propranolol on FS-induced reinstatement (Figure 9b). Two-
way repeated-measures FS × 10 mg/kg propranolol treatment ANOVA 
showed a significant main effect of propranolol (F1,15=7.018; p<0.05) 
but not FS and a significant interaction between 10 mg/kg propranolol 
treatment and FS (F1,15=5.116; p<0.05). Post-hoc examination of 
reinstatement in each group revealed that FS significantly reinstated 
place preference in vehicle-treated but not 10 mg/kg propranolol-
treated mice (t15=2.729; p<0.05) and that time spent in the cocaine 
compartment was significantly reduced by propranolol after FS 
(t15=2.411; p<0.05) but not under basal conditions. 
 
Figure 9 The nonselective β-AR antagonist propranolol blocks stress-induced 
reinstatement. Data represent the time spent in the cocaine (Coc) compartment 
(sec±SE) during the final extinction session previous reinstatement testing (Ext) and 
during reinstatement testing after forced swim (FS) after pretreatment with vehicle 
(V) or propranolol (Pro). Significant interactions between FS and Pro were found in 
mice tested at the 5 mg/kg (i.p.; a; n=7) and 10 mg/kg (i.p.; b; n=16) Pro doses 
(p<0.05). In each case, post-hoc testing showed that FS increased time spent in the 
Coc compartment after treatment with V (#p<0.05) but not Pro. Further, time spent in 
the Coc compartment was significantly reduced following Pro compared to V at the 
10 mg/kg, but not 5 mg/kg, Pro dose (@p<0.05). 
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Cocaine 
The effects of propranolol (5 or 10 mg/kg, i.p.) on cocaine-
induced reinstatement are shown in Figure 10. Neither propranolol 
dose blocked cocaine-induced reinstatement. The effect of 5 mg/kg 
propranolol was tested in nine mice (Figure 10a). Two-way cocaine × 
5 mg/kg propranolol treatment condition ANOVA showed a significant 
overall effect of cocaine (F1,8=9.731; p<0.05) on time spent in the 
cocaine compartment. However, no significant main effect of 
propranolol treatment condition or interaction between propranolol and 
cocaine-induced reinstatement was found. In all 11 mice were tested 
for the effect of 10 mg/kg propranolol on cocaine-induced 
reinstatement (Figure 10b). Similar to the lower propranolol dose, 
two-way cocaine × 10 mg/kg propranolol treatment condition ANOVA 
showed a significant overall effect of cocaine (F1,10=13.624; p<0.01) 
on time spent in the cocaine compartment, with no main effect of 
propranolol treatment condition and no interaction between 
propranolol treatment and cocaine-induced reinstatement. 
 
Figure 10 The non-selective β-AR antagonist propranolol does not block cocaine-
induced reinstatement. Data represent the time spent in the cocaine (Coc) 
compartment (sec±SE) during the final extinction session before the reinstatement 
testing (Ext) and during reinstatement testing after administration of cocaine (C; 
15 mg/kg, i.p.) following pretreatment with vehicle (V) or 5 mg/kg (i.p.) propranolol 
(Pro; n=9; a) or pretreatment with V or 10 mg/kg (i.p.) Pro (n=11; b). In both cases 
significant main effects of C (*p<0.05) but no C × Pro interactions were found. 
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Yohimbine 
The effects of propranolol (5 or 10 mg/kg, i.p.) on yohimbine-
induced reinstatement are shown in Figure 11. Propranolol blocked 
yohimbine-induced reinstatement at the 10 mg/kg, but not at the 
5 mg/kg dose. The effect of 5 mg/kg propranolol was tested in eight 
mice (Figure 11a). Two-way repeated-measures yohimbine × 5 mg/kg 
propranolol treatment condition ANOVA showed a significant overall 
effect of yohimbine (F1,7=7.865; p<0.05) on time spent in the cocaine 
compartment. However, no significant main effect of 5 mg/kg 
propranolol treatment condition or interaction between 5 mg/kg 
propranolol and yohimbine-induced reinstatement was found. The 
effect of 10 mg/kg propranolol on yohimbine-induced reinstatement 
was tested in 10 mice (Figure 11b). In contrast to the lower 
propranolol dose, 10 mg/kg propranolol prevented reinstatement after 
yohimbine administration. Two-way repeated-measures yohimbine 
reinstatement × 10 mg/kg propranolol treatment condition ANOVA 
failed to show significant main effects of yohimbine or propranolol 
(p=0.06) However, a significant interaction between 10 mg/kg 
propranolol treatment × yohimbine-induced reinstatement was found 
(F1,9=10.563; p=0.01). Post-hoc analyses showed that yohimbine 
significantly increased the time spent in the cocaine compartment in 
vehicle-pretreated (paired t-test; two-tailed t9=2.334; p<0.05) but not 
propranolol-pretreated mice, and that time spent in the cocaine 
compartment after yohimbine was significantly reduced in propranolol-
pretreated mice compared with vehicle controls (t9=2.728; p<0.05). 
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Figure 11 The nonselective β-AR antagonist propranolol dose-dependently blocks 
yohimbine-induced reinstatement. Data in (a) represent the time spent in the cocaine 
(Coc) compartment (sec±SE) during the final extinction session before the 
reinstatement testing (Ext) and during reinstatement testing after administration of 
yohimbine (Y; 2 mg/kg, i.p.) after pretreatment with vehicle (V) or 5 mg/kg (i.p.) 
propranolol (Pro; n=8). A significant main effect of Y (*p<0.05) but no Y × Pro 
interaction was found at this dose. The effect of 10 mg/kg (i.p.) Pro (n=10) on Y-
induced reinstatement is shown in (b). A significant interaction between Y and Pro was 
found at this dose (p<0.05). Post-hoc testing showed that Y increased time spent in 
the Coc compartment after treatment with V (#p<0.05) but not ICI. Further, time 
spent in the Coc compartment was significantly reduced following 10 mg/kg Pro 
compared to V (@p<0.05). 
Effects of Betaxolol and ICI 118,551 on FS-Induced 
Reinstatement 
As FS-induced reinstatement seemed to involve β-AR but not -
1 ARs, mice were tested with the β-1 AR selective receptor antagonist, 
betaxolol (10 mg/kg, i.p.), or the β-2 AR selective antagonist, ICI-
118551 (5 mg/kg, i.p.), in order to determine the role of β receptor 
subtypes in reinstatement by FS (Figure 12). ICI-118551 (Figure 12b) 
but not betaxolol (Figure 12a) blocked FS-induced reinstatement. The 
effect of betaxolol was tested in 11 mice. Two-way repeated-measures 
ANOVA showed a significant main effect of FS on time spent in the 
cocaine compartment (F1,10=9.762; p<0.05) but no effect of betaxolol 
or FS × betaxolol reinstatement. In all, 11 mice were tested for the 
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effect of ICI-118551 on FS-induced reinstatement. Two-way repeated-
measures ANOVA showed no main effects of ICI-118551 or FS on time 
spent in the cocaine compartment. However, a significant ICI-118551 
× FS interaction was observed (F1,10=9.364; p<0.05). Post-hoc 
analysis showed that FS produced significant reinstatement in vehicle, 
but not ICI-118551, treated mice (t10=2.874; p<0.05). 
 
Figure 12 The β-2 AR selective antagonist ICI-118551 but not the β-1 AR 
selective antagonist betaxolol blocks stress-induced reinstatement. Data in (a) 
represent the time spent in the cocaine (Coc) compartment (sec±SE) during the final 
extinction session prior to reinstatement testing (Ext) and during reinstatement testing 
after forced swim (FS) following pretreatment with vehicle (V) or betaxolol (Bet; 
10 mg/kg, i.p.; n=11). A significant main effect of FS (*p<0.05) but no FS × Bet 
interaction was found. The effect of ICI-118551 (ICI; 1 mg/kg, i.p.; n=11) on FS-
induced reinstatement is shown in (b). A significant interaction between FS and ICI 
was found (p<0.05). Post-hoc testing showed that FS increased time spent in the 
cocaine compartment after treatment with V (#p<0.05) but not ICI. 
Discussion 
Drug re-exposure and stress are commonly cited as 
precipitating factors for relapse in recovering cocaine addicts. Although 
both stimuli can trigger drug use, they do not necessarily do so 
through activation of completely overlapping neurobiological pathways. 
The present study poses the noradrenergic system as a likely mediator 
of relapse in response to stressors but not cocaine. First, activation of 
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central noradrenergic systems through disinhibition of noradrenergic 
signaling by administration of the -2 AR antagonist yohimbine or the 
more selective -2A AR antagonist BRL 44408 (Dwyer et al, 2010) is 
sufficient to induce reinstatement. Second, suppression of 
noradrenergic neurotransmission by the administration of the -2 AR 
agonist clonidine suppresses reinstatement by FS but not cocaine. 
Third, reinstatement by FS and yohimbine, but not cocaine, is blocked 
by the nonselective β-AR antagonist propranolol but not by the -1 AR 
antagonist, prazosin. In the case of FS, reinstatement is prevented by 
the selective β-2 AR antagonist ICI-118551, but not the selective β-1 
AR antagonist, betaxolol. Altogether, these findings suggest that 
elevated norepinephrine (NE) during periods of stress, but not after 
cocaine re-exposure, likely induces drug seeking through activation of 
β-2 ARs as measured in this mouse model of relapse. 
The apparent role for NE in stressor-induced relapse is also 
supported by previous studies. Icv NE administration reinstates 
cocaine seeking after SA (Brown et al, 2009), as does disinhibition of 
noradrenergic signaling through -2 adrenergic autoreceptor blockade 
(Lee et al, 2004; Feltenstein and See, 2006; Fletcher et al, 2008; 
Brown et al, 2009) and, in some cases, blockade of NE reuptake (Platt 
et al, 2007, but see Schmidt and Pierce, 2006). Conversely, 
suppression of stressor-induced NE release through administration of 
-2 AR agonists such as clonidine (Tjurmina et al, 1999) attenuates 
stress-induced drug seeking after SA of cocaine (Erb et al, 2000), 
heroin (Shaham et al, 2000a, 2000b), alcohol (Le et al, 2005; Dzung 
Lê et al, 2009), or a heroin–cocaine mixture (Highfield et al, 2001) in 
rats, stress-induced reinstatement of morphine-induced place 
preference in rats (Wang et al, 2001) and drug craving induced by 
stress imagery in heroin-dependent human subjects (Sinha et al, 
2007). 
Although stress-induced reinstatement was blocked using 
propranolol and clonidine, these pretreatments failed to alter 
reinstatement in response to cocaine, even though clonidine has been 
shown to prevent cocaine-induced increases in brain extracellular NE 
levels (Florin et al, 1994). Considering that cocaine, like other NET 
blockers that have been shown to induce reinstatement (Platt et al, 
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2007), markedly elevates central NE levels (Reith et al, 1997; Li et al, 
1996), and that elevation of central NE is sufficient to induce 
reinstatement (Brown et al, 2009), our findings suggest that cocaine-
responsive processes activated either concurrently with or downstream 
from noradrenergic systems are sufficient for relapse in the absence of 
a NE response. This assertion is consistent with a number of reports 
suggesting that many neurobiological systems underlying stress-
induced cocaine seeking (eg, CRF and κ-opioid) do not completely 
overlap with those underlying reinstatement in response to cocaine 
delivery (Erb et al, 1998; Shaham et al, 1998; Redila and Chavkin, 
2008) and is supported by studies showing that suppression of 
noradrenergic neurotransmission through -2 AR activation (Erb et al, 
2000) or antagonism of central β-ARs (Leri et al, 2002) blocks stress- 
but not cocaine-induced reinstatement in rats, as well as by findings 
that mixed - and β-adrenergic receptor antagonist drugs do not 
attenuate the subjective responses to smoked cocaine, despite 
reducing peripheral adrenergic responses (Sofuoglu et al, 
2000a, 2000b). However, it should be noted that other studies have 
indicated that noradrenergic neurotransmission may be involved in 
cocaine-induced reinstatement in monkeys (Platt et al, 2007) and rats 
(Zhang and Kosten, 2005). 
Our finding that propranolol blocks stressor-induced 
reinstatement is supported by those of Leri et al (2002), who found 
that administration of a combination of β-1 and β-2 AR antagonists 
directly into brain regions implicated in stressor-induced cocaine 
seeking blocks footshock-induced reinstatement after self-
administration in rats. Propranolol has also been found to block 
reinstatement resulting from NET blockade after self-administration in 
monkeys (Platt et al, 2007). Further, as β-AR are Gs G-protein coupled 
receptors, the findings are consistent with a report that forced swim- 
but not cocaine-induced reinstatement of conditioned place preference 
is dependent on cAMP and CREB activation in mice (Kreibich and 
Blendy, 2004). Interestingly, β-blockers have been reported to 
attenuate anxiety-like effects resulting from cocaine delivery (Schank 
et al, 2008; elevated plus maze) or cocaine withdrawal (Harris and 
Aston-Jones, 1993; defensive burying). Thus, to the extent that these 
anxiogenic effects contribute to drug craving and relapse during 
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withdrawal and/or continued cocaine use, our findings provide further 
evidence of potential utility of β-blockers for the management of 
cocaine addiction. Despite these findings, clinical trials examining the 
ability of propranolol to promote drug abstinence in cocaine-dependent 
individuals have found only modest improvement (Kampman et al, 
2001, 2006) potentially because of the inability of propranolol to 
attenuate cocaine-induced craving and rewarding effects. Consistent 
with our own findings, it has been reported that propranolol fails to 
decrease cocaine-induced reinstatement in rats (Leri et al, 2002) and 
monkeys (Platt et al, 2007) and that drugs with β-AR antagonist 
properties fail to alter cocaine's subjective effects (Sofuoglu et al, 
2000a, 2000b). In fact, it has been reported that propranolol can 
actually augment cocaine's locomotor (Harris et al, 1996 but see 
Vanderschuren et al, 2003), discriminative stimulus (Kleven and Koek, 
1997; but see Spealman, 1995), and reinforcing effects (Harris et al, 
1996). It may be that, because of the selective attenuation of stress-
induced cocaine seeking, targeting β-receptors may be more useful as 
an adjunct approach and/or only in subpopulations of cocaine-
dependent individuals whose use is stress driven. In support, 
Kampman et al (2001, 2006) found that propranolol significantly 
increased abstinence time only in cocaine-dependent individuals 
experiencing pronounced withdrawal symptoms, which for cocaine 
dependence include intense anxiety (Gawin and Kleber, 1986). 
In the present study, stressor-induced reinstatement seemed to 
involve β-2 AR, presumably within the CNS, but not β-1 AR. FS-
induced reinstatement was blocked by the selective β-2 AR antagonist 
ICI-118551 but not the β-1 AR antagonist betaxolol. This finding was 
somewhat surprising, considering that it has been previously reported 
that betaxolol blocked anxiety-like behavior during withdrawal from 
chronic cocaine administration (Rudoy and Van Bockstaele, 2007). The 
role of β-2 AR in stress- and anxiety-related processes is unclear. 
However, β-2 AR are found throughout the rat brain, including in the 
BNST (Rainbow et al, 1985) and the amygdala (Tiong and Richardson, 
1990), sites in which nonselective antagonism of β-AR has been shown 
to attenuate stressor-induced cocaine seeking (Leri et al, 2002) and in 
which β-2 AR have been implicated in affective, but not sensory or 
somatic, elements of pain (Deyama et al, 2008) or opiate withdrawal 
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(Watanabe et al, 2003). Confirmation that central but not peripheral β-
2 AR activation is required for stress-induced reinstatement will 
require further investigation. 
In contrast to propranolol, the -1 AR antagonist prazosin (1 or 
2 mg/kg) failed to alter reinstatement by any of the stimuli tested. The 
finding that prazosin did not alter cocaine-induced reinstatement was 
somewhat surprising considering that prazosin has been reported to 
attenuate cocaine-induced reinstatement after self-administration in 
rats (Zhang and Kosten, 2005) but not monkeys (Platt et al, 2007). 
This disparity in prazosin effects on cocaine-evoked reinstatement 
across studies could be attributable to a number of factors, including 
species, general approach/experimental parameters, and dose. A role 
for -1 ARs in a number of cocaine effects has been identified, 
including cocaine's reinforcing (Drouin et al, 2002; Wee et al, 2008 but 
see Woolverton, 1987), sensitizing (Jiménez-Rivera et al, 2006; Zhang 
and Kosten, 2007), locomotor stimulating (Drouin et al, 2002; Snoddy 
and Tessel, 1985 but see Vanderschuren et al, 2003), and 
discriminative stimulus (Spealman, 1995) effects. 
Our finding that yohimbine administration reinstates 
extinguished place preference in mice is consistent with previous 
reports that yohimbine reinstates extinguished cocaine seeking after 
SA in rats (Feltenstein and See, 2006; Fletcher et al, 2008; Brown et 
al, 2009) and monkeys (Lee et al, 2004) and impairs the extinction of 
cocaine-induce conditioned place preference in mice (Davis et al, 
2008). As we were able to block yohimbine-induced reinstatement 
with propranolol, we presumed that yohimbine's effects on cocaine 
seeking were attributable to disinhibition of noradrenergic activity 
resulting from antagonism of -2 adrenergic autoreceptors. Consistent 
with this, it has been reported that the highly selective -2 adrenergic 
receptor antagonist RS-79948 can induce reinstatement in monkeys 
(Lee et al, 2004) and that RS-79948- and yohimbine-induced 
reinstatement are blocked by the -2 adrenergic receptor agonist, 
clonidine (Lee et al, 2004). A similar clonidine-inhibited β-AR-
dependent mechanism has been reported to be involved in the 
reinstatement of extinguished cocaine seeking by the selective NET 
inhibitor, nisoxetine in squirrel monkeys (Platt et al, 2007). 
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Surprisingly however, in the present study, clonidine failed to block 
yohimbine-induced reinstatement. These findings are consistent with a 
recent report that clonidine failed to prevent yohimbine-induced 
reinstatement of cocaine seeking after SA in rats (Brown et al, 2009). 
It is unclear why clonidine is ineffective in blocking yohimbine-
induced reinstatement of cocaine seeking. However, there are two 
possibilities. First, yohimbine could be inducing reinstatement through 
a non--2 AR mechanism. In support, Davis et al (2008) reported that 
the impairment of extinction of cocaine-induced conditioned place 
preference and suppression of glutamate-induced electrophysiological 
responses in brain slices containing the bed nucleus of the stria 
terminalis by yohimbine were unaltered in -2A adrenergic receptor 
deficient mice and were not mimicked by the more selective -2A AR 
antagonist, atipamezole. Yohimbine has been reported to function as 
an agonist at 5-HT1A receptors (Winter and Rabin, 1992; Millan et al, 
2000). This 5-HT1A receptor agonist effect may be relevant to drug 
seeking, as yohimbine-induced reinstatement of extinguished alcohol 
seeking in rats is attenuated by the 5-HT1A receptor antagonist, WAY 
100635, as well as clonidine, but is minimally reduced by lesions of 
ascending noradrenergic systems (Dzung Lê et al, 2009). To further 
examine the role for -2 AR antagonism in reinstatement, we also 
tested mice with the selective -2A antagonist BRL 44408, a 
compound that has a 50-fold higher affinity for -2A AR relative to 5-
HT-1A receptors (Dwyer et al, 2010). Like yohimbine, this more 
selective -2A AR antagonist also produced robust reinstatement, 
suggesting that -2 AR antagonism alone is likely sufficient for 
reinstatement. Notably, if indeed yohimbine is working through a 
mechanism that is independent of -2 AR, our data suggest that this 
mechanism still involves β-AR. 
Secondly, clonidine itself is somewhat nonselective. Lower 
clonidine doses likely primarily target presynaptic -2 ARs, thereby 
competitively reversing yohimbine effects and generally suppressing 
noradrenergic neurotransmission through -2 AR-mediated auto-
inhibitory actions. Accordingly, at the lower (ie, 0.03 mg/kg) dose, 
clonidine prevented reinstatement by FS. In addition to attenuating NE 
release, higher clonidine doses also activate lower affinity postsynaptic 
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-2 ARs and/or bind to imidazoline I1 receptor sites (Bricca et al, 
1989; Eglen et al, 1998), thus mimicking components of the 
noradrenergic response despite indirectly reducing activation of -1 
and β-AR or producing nonnoradrenergic effects. On the basis of our 
finding that the higher (ie, 0.3 mg/kg) clonidine dose not only failed to 
attenuate yohimbine and FS-induced reinstatement but induced 
reinstatement on its own, we hypothesize that, similar to β-AR, these 
high-dose targets may contribute to reinstatement during stress. This 
finding is consistent with another report that high doses of clonidine 
can induce conditioned place preference in rats (Cervo et al, 1993). 
Future studies using putative imidazoline receptor ligands as well as 
other -2 AR agonists with relatively low affinity for imidazoline 
receptors (eg, guanabenz) are needed to determine the relative 
contribution of these receptor populations to reinstatement. Overall, 
this dose-dependent regulation of differential receptor populations with 
varying effects on drug seeking, along with the tendency of yohimbine 
to interact with multiple receptor targets, likely contributed to the 
observed variation in clonidine's ability to block yohimbine-induced 
reinstatement in this study and others. 
NE-dependent stress-induced reinstatement seems to involve 
projections from the lateral tegmental region of the brainstem to the 
bed nucleus of the stria terminalis (BNST) and/or the central nucleus 
of the amygdala (CeA) by the ventral noradrenergic bundle and 
activation β-ARs. In rats, stress- but not drug-induced reinstatement is 
attenuated by administration of clonidine into the lateral tegmentum, 
but not the LC (Shaham et al, 2000a, 2000b; heroin) or into the BNST 
(Wang et al, 2001; cocaine) or by delivery of a combination of β-1 and 
β-2 adrenergic receptor antagonists into the BNST or CeA (Leri et al, 
2002; cocaine). It has been postulated that NE released into these 
regions regulates the release of corticotropin releasing factor (CRF) 
which in turn can indirectly (by actions in the BNST; Erb et al, 2001) 
or directly (by actions in the ventral tegmental area; Wang et al, 
2005) activate mesocorticolimbic activity, thus producing drug-seeking 
behavior. The apparent lack of involvement of CRF (Shaham et al, 
1998; Erb et al, 1998) and NE (Erb et al, 2000, Leri et al, 2002, and 
present findings; but see Platt et al, 2007, Zhang and Kosten, 2005) in 
cocaine-induced reinstatement suggests that despite convergence 
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within the mesocorticolimbic system, the neurobiological pathways 
underlying drug and stress induced relapse are largely distinct. 
β-AR, specifically β-2 AR, have also been implicated in the post-
retrieval reconsolidation of cocaine-induced conditioned place 
preference in mice. Systemic propranolol (Bernardi et al, 2006; Fricks-
Gleason and Marshall, 2008) and intrabasolateral amygdalar ICI-
118551 (Bernardi et al, 2009) injections interfere specifically with the 
reconsolidation of conditioned place preference after retrieval without 
enhancing extinction learning. As, in our study, mice did not receive 
propranolol or ICI-118551 until after place preference had already 
been extinguished and as drug administration occurred immediately 
before to exposure of the reinstating stimuli, it is unlikely that effects 
on reconsolidation contributed to the observed attenuation of 
reinstatement. Nonetheless, the potential ability of β-2 AR antagonists 
to attenuate stress-evoked relapse and interfere with reconsolidation 
of drug-associated memories, establishes β-2 ARs as a target of 
interest for the treatment of addiction. 
In summary, these findings further suggest that central 
noradrenergic systems contribute to drug-seeking behavior during 
times of stress. Considering that repeated cocaine exposure is 
associated with progressive changes in brain noradrenergic systems 
(Belej et al, 1996; Macey et al, 2003; Baumann et al, 2004; Beveridge 
et al, 2005; Horne et al, 2008; Lanteri et al, 2008) and that early 
abstinence from cocaine in dependent individuals is associated with an 
exaggerated noradrenergic response (McDougle et al, 1994), targeting 
noradrenergic neurotransmission, particularly β-2 AR, may be 
particularly beneficial for the management of relapse in cocaine-
dependent individuals whose drug use is stress-related. 
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